Prevention Trials
Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY18956
Hybrid Type 1 Effectiveness Implementation Trial of a Proactive Smoking Cessation Electronic Visit for Scalable Delivery via Primary Care
We will conduct a two-arm clinic-randomized clinical trial (N=672) to examine the effectiveness of a smoking cessation electronic visit (e-visit) vs. treatment as usual (TAU) for smoking cessation across 21 MUSC primary care practices. Main outcomes include: 1) evidence-based smoking cessation treatment utilization (medication, psychosocial cessation counseling), 2) reduction in cigarettes per day, and 3) biochemically verified 7-day PPA at six-month follow-up. We hypothesize that smokers randomized to the e-visit condition will have significantly better cessation outcomes relative to TAU. Secondary outcomes will focus on implementation of the e-visit at the patient, provider, and organizational levels.
Study InformationSTUDY19843
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years.
Study InformationSTUDY21506
Addressing Rural Cancer Disparities via Proactive Smoking Cessation Treatment within Primary Care: A Hybrid Type 1 Effectiveness Implementation Trial of a Scalable Smoking Cessation Electronic Visit
We will conduct a Hybrid Type I effectiveness-implementation trial to comprehensively assess effectiveness of a proactive electronic visit (e-visit) for smoking cessation relative to treatment as usual (TAU) while simultaneously evaluating implementation when delivered across rural primary care settings. In Aim 1, we will conduct a stepped-wedge, cluster-randomized clinical trial (N=288) to examine the effectiveness of the smoking cessation e-visit vs. TAU for smoking cessation across seven rural (Rural-Urban Commuting Area codes 4-10) primary care practices in South Carolina. In Aim 2, we will evaluate e-visit implementation outcomes across rural South Carolina primary care settings at patient, provider, and organizational levels. Main outcomes include: 1) biochemically verified 7-day PPA (point prevalence of abstinence) at six-month follow-up, 2) reduction in cigarettes per day, and 3) evidence-based smoking cessation treatment utilization (medication, psychosocial cessation counseling). We hypothesize that rural smokers randomized to the e-visit condition will have significantly better cessation outcomes relative to TAU.
Study InformationSTUDY21923
Impact of Cigarette and E Cigarette Menthol Regulation on Current Smokers of Menthol Cigarettes.
Assess the impact of simulated cigarette and e-cigarette menthol regulations on tobacco use patterns among current menthol smokers. Primary outcomes are a) changes in cigarettes per day (CPD) through Week 6, and secondary outcomes include b) e-cigarette use, and c) ability to remain abstinent. Hypothesis: Assignment to non-menthol cigarettes and assignment to menthol e-liquid will a) reduce cigarettes per day, b) increase e-cigarette use, and c) increase the ability to remain abstinent. We hypothesize an interaction such that effects on tobacco use patterns will be greatest for individuals who receive both non-menthol cigarettes and menthol e-liquid.
Study InformationSTUDY22361
Non-cigarette tobacco products as harm reduction tools in smokers who failed to quit with traditional methods
Assess the impact of a switching approach on cigarette smoking behavior. Assess the impact of a switching approach on measures of harm.
Study InformationSTUDY23008
A clinical trial of adaptive treatment for early smoking cessation relapse
Aim 1: To determine if, among non-responders to an initial course of FDA-approved smoking cessation medication (either varenicline or combination NRT), it is better to continue use of the same medication or to switch to another. Hypothesis: Among smokers who have not yet responded to one FDA-approved medication, switching to another FDA-approved medication will result in greater success at short-term follow-up, using a clinically relevant and objective measure of success (7-days non-smoking with CO < 6ppm), as compared to medication continuation. Aim 2: To determine if, among non-responders to two courses of FDA-approved medications, it is better to continue use of these same medications or switch to a harm reduction alternative (e-cigarette). Hypothesis: Among smokers who have not yet responded to two courses of FDA-approved pharmacotherapy, switching to e-cigarettes will result in greater abstinence from cigarettes at short-term follow-up. Aim 3: To assess 6-month cessation outcomes among smokers who received only FDA-approved cessation medications (varenicline or combination NRT) vs. a harm reduction alternative (e-cigarette). Hypothesis: Among smokers who have not responded to treatment after two courses of pharmacotherapy, a harm reduction approach will result in higher rates of abstinence at 6 months than another course of pharmacotherapy.
Study InformationSTUDY23716
Evaluating a tobacco harm reduction strategy among clients enrolled in substance use disorder treatment
Evaluate if switching to ENDS leads to greater rates of 7-day biologically confirmed point prevalence abstinence (PPA) from cigarette smoking at 12 weeks compared to quitting with NRT among those enrolled in SUD treatment. Evaluate patient, provider, and organizational-level implementation outcomes using mixed methods according to the Proctor framework. Outcomes include: acceptability, appropriateness and feasibility. Quantitative data will be supplemented with in-depth interviews with patients (n=25), providers (n=10), and organizational stakeholders (n=6) to identify barriers and facilitators to implementation
Study InformationSTUDY23406
Randomized controlled trial of varenicline to treat tobacco and cannabis co-use
Evaluate rates of 7-day biochemically confirmed point prevalence abstinence (PPA) from cigarettes at the 12-week end of treatment (EOT) visit comparing varenicline + psychosocial intervention to the placebo + psychosocial intervention participants.
Study InformationSTUDY24898
A Prospective Trial of Varenicline and Incentives for E Cigarette Cessation in Adults Who Co Use Cannabis
Compare rates of 7-day biochemically-confirmed e-cigarette abstinence with cigarette abstinence rates from the parent R37 co-use sample (as a historical controls). Assess changes in cannabis use during e-cigarette cessation treatment among the new sample of participants enrolled in this extension. Assess for a dose-dependent impact of cannabis co-use severity on e-cigarette cessation.
Study InformationSTUDY25156
A Novel Harm Reduction Approach for Oncology Outpatients who Smoke and Refuse Traditional Tobacco Treatment
Assess the impact of a switching approach on cigarette smoking behavior. To characterize key determinants of intervention implementation outcomes using a mixed methods approach.
Study Information